for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

UCB SA

UCB.BR

Latest Trade

90.54EUR

Change

-0.30(-0.33%)

Volume

222,792

Today's Range

89.80

 - 

91.02

52 Week Range

60.18

 - 

114.45

As of on the Euronext Brussels ∙ Minimum 15 minute delay

Pricing

Previous Close
90.84
Open
90.90
Volume
222,792
3M AVG Volume
5.88
Today's High
91.02
Today's Low
89.80
52 Week High
114.45
52 Week Low
60.18
Shares Out (MIL)
189.12
Market Cap (MIL)
17,610.54
Forward P/E
18.70
Dividend (Yield %)
0.96

Next Event

Ucb SA at KBC Groep NV Roadshow (Virtual)

Latest Developments

More

UCB: Approval Of VIMPAT CV By FDA For PGTS And Pediatric Use On Epilepsy

UCB Boosts Gene Therapy With New Acquisition, Collaboration

UCB Signs Agreement To Acquire New Campus In UK

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About UCB SA

Ucb SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.

Industry

Biotechnology & Drugs

Contact Info

Allee de la Recherche, 60

1070

Belgium

+32.2.5599999

https://www.ucb.com

Executive Leadership

Jean-Christophe Tellier

Chairman of the Executive Committee, Chief Executive Officer, Executive Director

Evelyn Diego du Monceau de Bergendal

Non-Executive Chair of the Board

Pierre L. Gurdjian

Independent Non-Executive Vice Chairman of the Board

Sandrine Dufour

Chief Financial Officer, Executive Vice President, Member of the Executive Committee

Jean-Luc Fleurial

Chief Human Resource Officer, Executive Vice President, Member of the Executive Board

Key Stats

2.00 mean rating - 18 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2017

4.5K

2018

4.6K

2019

4.9K

2020(E)

5.2K
EPS (EUR)

2017

4.820

2018

4.780

2019

5.200

2020(E)

4.836
Price To Earnings (TTM)
22.93
Price To Sales (TTM)
3.39
Price To Book (MRQ)
2.41
Price To Cash Flow (TTM)
16.01
Total Debt To Equity (MRQ)
40.65
LT Debt To Equity (MRQ)
34.74
Return on Investment (TTM)
8.14
Return on Equity (TTM)
6.45

Latest News

Latest News

BRIEF-UCB And Ferring Pharmaceuticals Announce Co-Promotion Of Cimzia®

* UCB AND FERRING PHARMACEUTICALS ANNOUNCE CO-PROMOTION OF CIMZIA® (CERTOLIZUMAB PEGOL) FOR THE TREATMENT OF ADULTS WITH MODERATE TO SEVERE CROHN'S DISEASE

BRIEF-UCB Acquires Engage Therapeutics

* INITIAL UPFRONT PAYMENT OF US$ 125 MILLION AND FURTHER POTENTIAL MILESTONE PAYMENTS OF UP TO US$ 145 MILLION, TOTAL POTENTIAL CONSIDERATION OF UP TO US$ 270 MILLION

BRIEF-UCB Acquires Ra Pharmaceuticals And Updates 2020 Financial Guidance

* COMPLETES ACQUISITION OF RA PHARMACEUTICALS – TO DELIVER DIFFERENTIATED THERAPIES TO PATIENTS

BRIEF-UCB Updates On Phase 2B Padsevonil Safety And Efficacy Study In Epilepsy

* UCB PROVIDES AN UPDATE ON PHASE 2B PADSEVONIL SAFETY AND EFFICACY STUDY IN EPILEPSY (ARISE)

BRIEF-UCB Announces Appointment Of Sandrine Dufour As New CFO

* UCB ANNOUNCES APPOINTMENT OF SANDRINE DUFOUR AS NEW CHIEF FINANCIAL OFFICER

BRIEF-Advanz Pharma Announces Definitive Agreement To Acquire The Rights To A Portfolio Of Alprostadil Products From UCB For Approximately $84 Mln

* ADVANZ PHARMA CORP. LIMITED ANNOUNCES DEFINITIVE AGREEMENT TO ACQUIRE THE RIGHTS TO A PORTFOLIO OF ALPROSTADIL PRODUCTS FROM UCB S.A. FOR APPROXIMATELY $84 MILLION

BRIEF-UCB FY Revenue Up At 4.9 Billion Euros

* FY PROFIT AMOUNTED TO EUR 817 MILLION OF WHICH EUR 792 MILLION (-1%; +15% CER) IS ATTRIBUTABLE TO UCB SHAREHOLDERS

Belgium's UCB raises 2019 forecasts after net sales beat in fourth quarter

Belgian drugmaker UCB <UCB.BR> raised its revenue and earnings per share guidance for 2019 on Friday, helped by better-than-expected net sales due to strong demand for its Cimzia and Vimpat drugs in the fourth quarter.

Belgium's UCB says psoriasis drug beats AbbVie's Humira in trial

UCB SA said on Friday its experimental plaque psoriasis drug produced better results compared to AbbVie Inc's blockbuster drug, Humira, in reducing the severity of the disease.

Belgium's UCB to buy Ra Pharmaceuticals in $2.1 billion cash deal

UCB has agreed to acquire U.S.-based Ra Pharmaceuticals for $2.1 billion, both companies reported on Thursday, in a deal that will enable the Belgian drugmaker to offer new treatment opportunities for several rare diseases in neurology and immunology.

Belgium's UCB to buy Ra Pharmaceuticals for $2.1 bln

UCB has agreed to acquire U.S.-based Ra Pharmaceuticals for $2.1 billion, in a deal that will enable the Belgian drugmaker to offer new treatment opportunities for several rare diseases in neurology and immunology.

CORRECTED-BRIEF-UCB's Midazolam Nasal Spray Granted Orphan Drug Designation

* FDA ACCEPTS NEW DRUG APPLICATION (NDA) TO REVIEW MIDAZOLAM NASAL SPRAY

BRIEF-Cimzia Is The First Therapy To Demonstrate Positive Results In A 52-Week, Placebo Controlled Non-Radiographic Axial Spondyloarthritis Study

* CIMZIA® (CERTOLIZUMAB PEGOL) IS THE FIRST THERAPY TO DEMONSTRATE POSITIVE RESULTS IN A 52-WEEK, PLACEBO CONTROLLED NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS STUDY

BRIEF-UCB Announces Positive CHMP Opinion For Cimzia®

* UCB ANNOUNCES POSITIVE CHMP OPINION FOR CIMZIA® (CERTOLIZUMAB PEGOL) IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS

BRIEF-UCB Q1 Revenue Down At 1.07 Billion Euros

* FINANCIAL OUTLOOK 2018 CONFIRMED: REVENUE EXPECTED TO REACH € 4.5 - 4.6 BILLION

BRIEF-UCB Acquires Midazolam Nasal Spray From Proximagen

* UCB TO EXPAND EPILEPSY PORTFOLIO WITH STRATEGIC ACQUISITION OF MIDAZOLAM NASAL SPRAY FROM PROXIMAGEN

BRIEF-UCB Acquires Element Genomics

* UCB STRENGTHENS RESEARCH CAPABILITIES WITH ACQUISITION OF ELEMENT GENOMICS, A DUKE UNIVERSITY BIOTECH SPIN-OFF

BRIEF-UCB: Publication On Cimzia® Shows Psoriatic Arthritis Patients Achieved Treatment Targets

* PUBLICATION ON CIMZIA® SHOWS PSORIATIC ARTHRITIS PATIENTS ACHIEVED TREATMENT TARGETS

BRIEF-UCB Files For Acceptance With China Food And Drug Administration For Cimzia

* UCB ANNOUNCES FILING ACCEPTANCE WITH CHINA FOOD AND DRUG ADMINISTRATION FOR CIMZIA FOR TREATMENT OF MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS

BRIEF-UCB SA U.S. Food And Drug Administration (FDA) Approves Label Change For UCB’S Cimzia®

* U.S. FOOD AND DRUG ADMINISTRATION (FDA) APPROVES LABEL CHANGE FOR UCB’S CIMZIA®

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up